Daily Alpha · Reddit
· Midday Alpha · by Buzzberg Research
On Reddit, one poster rebought Nvidia after a panic sale while another argued its margins could compress, alongside single-stock theses on Iovance, Elite Pharmaceuticals and ZEEL.
Themes on this desk
Nvidia dip
A r/wallstreetbets poster bought Nvidia back at $169 after selling at $160, while a r/ValueInvesting author argues gross margins can compress from a 79% peak toward the low-60% range.
Highest engagement
by score · day changeA longtime Iovance follower builds a bull case on Amtagvi revenue growth
The author cites real Amtagvi revenue growth, improving margins, an expanding lung-cancer and sarcoma pipeline and 2027 regulatory catalysts.
$IOVA - The Stock I've been watching for nearly 4 years straight Ticker:
The post also lists clinical, adoption, dilution and profitability risks.
Watch Iovance's 2027 regulatory catalysts.
Source →Elite Pharmaceuticals bull case rests on about 5.9x trailing operating income
The author reports Q2 FY2027 revenue of $40.1 million, up 24% from Q1, and calls ELTP cheap at about 5.9x trailing operating income given renewed growth, net cash and a large-market pipeline.
ELTP Q2 FY2027 —Thorough analysis **A Breakout Quarter** • **Revenue $40.1M** — up 24% from Q1 and 10% from a
A Nasdaq uplisting is the named catalyst.
Watch Elite's Nasdaq uplisting.
Source →ZEEL's ₹600 crore buyback at ₹91 is pitched as support despite low acceptance
The author argues the low-acceptance buyback still provides structural support, while sum-of-parts value and a clearing SEBI overhang make ZEEL an attractive value or swing long.
ZEEL ₹600Cr Buyback at ₹91 — The Real Acceptance Ratio Math & Why It’s Now a Value Play A lot
The ₹91 buyback price anchors the thesis.
Watch Clearing of the SEBI overhang.
Source →Vistra's Q3 EBITDA rose more than 50% and guidance narrowed higher
A filing review values Vistra at about 9.1x 2026 EBITDA and notes the 10-Q balance sheet does not show the current position.
VST Q3: EBITDA up 50%+ and guidance narrowed higher, but the balance sheet in the 10-Q doesn't show the current
The author flags the 10-K and Series B redemption as checks, without a clear directional call.
Watch Vistra's 10-K and Series B redemption.
Source →A NATCO Pharma holder stays long despite a 60% profit decline
The author holds through a weak Q2 FY27, citing upgraded FY27 PAT guidance, sequential revenue recovery, net cash and US launches.
NATCO Pharma – Still Holding Despite the 60% Profit Decline. Anyone With Me?
Upgraded FY27 PAT guidance is one of the reasons the author gives for staying long.
Watch NATCO's US launches.
Source →Most argued
by comments per upvoteAnthropic is reportedly 6x oversubscribed at up to a $1.4 trillion valuation
The post weighs bull and bear cases on Anthropic's reported IPO oversubscription and valuation without a firm directional call.
Anthropic is reportedly 6× oversubscribed at up to a $1.4T valuation. At what point does it all add up?
The debate is whether the $1.4 trillion valuation adds up.
Watch Anthropic's IPO.
Source →Czechoslovak Group is down 60% in a year as a poster asks whether it is a falling knife
The post raises Czechoslovak Group as an EU defence play down 60% in a year, questioning whether it is a falling knife or an opportunity.
Czechoslovak Group (CSG) Has any one heard of or considered the Czechoslovak Group?
The question is whether the 60% decline creates an opportunity in an EU defence name.
Source →A poster asks whether Forgent Power Solutions is a hidden AI infrastructure winner
The author presents Forgent Power Solutions as a potential AI infrastructure beneficiary with strong growth and backlog but asks whether now is a good time to buy.
Forgent Power Solutions(NYSE: FPS) : The Hidden AI Infrastructure Winner?
The thesis ties FPS to AI infrastructure demand.
Source →